This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and genetherapy, transforming both clinical research and post-market care. These therapies involve modifying a patient’s cells or genes to treat or prevent diseases, with the promise of long-lasting effects.
Cell & GeneTherapy coverage on Pharmaceutical Technology is supported by Cytiva. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and genetherapies. By Cytiva Thematic.
Zebra Medical CEO Ohad Arazi said that expanding from radiology to orthopaedic surgery supports their mission of taking advantage of machine learning and computer vision to benefit patients achieve better care everywhere with more readily available resources. UniQure/CSL haemophilia B genetherapy curbs bleeding in phase 3.
Standard Velocity site features: Private exam rooms Comfortable patient reception areas Facilities for extended-stay PK studies Ample parking Secure monitoring rooms and workstations equipped with phones and high-speed internet Individual and secure workstations for research staff Regulatory document processing area EDC capabilities Secure record storage (..)
This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes. By editing these genes, researchers can effectively neutralize their cancer-promoting effects.
Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.
Novartis has been steadily building itself into a radio-oncology powerhouse in the last few years, seeing the category as one of four pillars of its cancer business, along with cell and genetherapy, targeted drugs and immunotherapeutics. In 2018 it paid $2.1
The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells.
Bayer recently formed its own cell and genetherapy platform as part of its transformation strategy for Pharmaceuticals. The platform already has potentially ground-breaking medical innovations in clinical development, such as a therapy for the treatment of Parkinson’s. percent (Fx & portfolio adj.) to 4.494 billion euros.
We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and genetherapies, cause many of the same symptoms and work through final common pathways. However, a drawback is that the dose and neuronal specificity of genetherapy is still poorly understood even in translational models.
Six patients with dementia went to Mexico for an unproven genetherapy, a biotech CEO claims ( STAT ).
Avrobio changes course after FDA closes path for speedy genetherapy approval ( BioPharmaDive ).
Radiology Partners, Aidoc talk AI adoption, handling bias, FDA actions ( MedtechDive ).
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content